Astellas Pharma Inc. (TYO:4503)
2,099.00
+5.00 (0.24%)
At close: Dec 26, 2025
Astellas Pharma Revenue
Astellas Pharma had revenue of 524.32B JPY in the quarter ending September 30, 2025, with 13.37% growth. This brings the company's revenue in the last twelve months to 2.01T, up 13.24% year-over-year. In the fiscal year ending March 31, 2025, Astellas Pharma had annual revenue of 1.91T with 19.25% growth.
Revenue (ttm)
2.01T
Revenue Growth
+13.24%
P/S Ratio
1.87
Revenue / Employee
147.09M
Employees
13,643
Market Cap
3.76T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.91T | 308.65B | 19.25% |
| Mar 31, 2024 | 1.60T | 85.05B | 5.60% |
| Mar 31, 2023 | 1.52T | 222.46B | 17.16% |
| Mar 31, 2022 | 1.30T | 46.64B | 3.73% |
| Mar 31, 2021 | 1.25T | -51.32B | -3.94% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.42T |
| Otsuka Holdings | 2.42T |
| Daiichi Sankyo Company | 1.98T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |
| Eisai | 804.39B |
Astellas Pharma News
- 10 days ago - Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer - Nasdaq
- 12 days ago - Why Is Monte Rosa Stock Trading Higher Today? - Benzinga
- 17 days ago - Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines - GlobeNewsWire
- 18 days ago - Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium - PRNewsWire
- 23 days ago - Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting - PRNewsWire
- 4 weeks ago - EMA Validates Review Of Astellas' PADCEV And KEYTRUDA Combination In Bladder Cancer - Nasdaq
- 5 weeks ago - Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Nasdaq
- 7 weeks ago - Q2 2026 Astellas Pharma Inc Earnings Presentation Transcript - GuruFocus